Cargando…

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB

BACKGROUND: Trametinib (Tr) has been applied in the treatment of children with various tumor types, often for prolonged periods. Little is known regarding immune function (IF) following prolonged Tr in this age group. OBJECTIVE: Describe laboratory measures of IF in children on Tr. METHOD: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moukhaiber, Perla, Samolej, Anna, Somsri, Palita, McCowage, Geoffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neurofibromatosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715110/ http://dx.doi.org/10.1093/neuonc/noaa222.620

Ejemplares similares

NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
por: Toledano, Helen, et al.
Publicado: (2020)

NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020)

NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA
por: Hounjet, Celine D, et al.
Publicado: (2020)

NFB-11. WHITE MATTER DIFFERENCES IN CHILDREN WITH NF1 COMPARED TO CONTROLS
por: Bruckert, Lisa, et al.
Publicado: (2020)

NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020)

NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2
por: Hemenway, Molly, et al.
Publicado: (2020)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
por: Chaffee, Blake, et al.
Publicado: (2020)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

NFB-04. EXAMINING DIFFUSION, ARTERIAL SPIN-LABELED PERFUSION, AND VOLUMETRIC CHANGES IN THE NEUROFIBROMATOSIS TYPE 1 BRAIN USING AN ATLAS-BASED, MULTI-PARAMETRIC APPROACH
por: Tam, Lydia, et al.
Publicado: (2020)

NFB-16. mTOROPATHIES AND SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: PREDICTIVE VALUE OF GERMINAL TSC1/2 MUTATIONS SCREENING IN FAMILIAL CASES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2020)

NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM
por: Mueller, Sabine, et al.
Publicado: (2020)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
por: Fisher, Michael J, et al.
Publicado: (2020)

NFB-12. Effect of trametinib on leg length discrepancy in a child with NF1 related plexiform neurofibroma
por: Pradeep, Celia, et al.
Publicado: (2022)

NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022)

NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis"
por: Mavrea, Kalliopi, et al.
Publicado: (2022)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
por: Hemenway, Molly
Publicado: (2022)

NFB-03. Neurological manifestations in children and adolescents with Neurofibromatosis type 1 - Implications for management and surveillance
por: Angelova-Toshkina, Daniela, et al.
Publicado: (2022)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

NFB-06. Laser Interstitial Thermal Therapy as a Radiation-Sparing Approach for Children with Cancer Predisposition
por: Guadix, Sergio, et al.
Publicado: (2022)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
por: Marks, Asher, et al.
Publicado: (2022)

NFB-09. Treatment of cardiac fibroma in aPTCH1-mutated Gorlin syndrome with medulloblastoma
por: Piccolo, Gianluca, et al.
Publicado: (2022)

NFB-23. Extent of tumor but not location may be predictive of longitudinal disease severity in children with NF1-associated gliomas requiring treatment
por: Chaturvedi, Sneha, et al.
Publicado: (2022)

NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma
por: Zhang, Kailong, et al.
Publicado: (2022)

NFB-01. Central nervous system tumors in Von Hippel-Lindau multisystem disorder: are there preventive approaches to escape tumor initiation at a young age?
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2022)

Psychosocial Assessment Using Telehealth in Adolescents and Young Adults With Cancer: A Partially Randomized Patient Preference Pilot Study
por: Chalmers, John Alexander, et al.
Publicado: (2018)

Ub-ISAP: a streamlined UNIX pipeline for mining unique viral vector integration sites from next generation sequencing data
por: Kamboj, Atul, et al.
Publicado: (2017)

Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and ALK Genotyping via Cell-Free Circulating Tumor DNA Profiling
por: Kahana-Edwin, Smadar, et al.
Publicado: (2021)

KRAS-driven model of Gorham-Stout disease effectively treated with trametinib
por: Homayun-Sepehr, Nassim, et al.
Publicado: (2021)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
por: Tudor, Diana Valentina, et al.
Publicado: (2021)

Molecular profiling of childhood cancer: Biomarkers and novel therapies
por: Saletta, Federica, et al.
Publicado: (2014)

Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis
por: Manoharan, Neevika, et al.
Publicado: (2021)

Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas
por: Klotz, Barbara, et al.
Publicado: (2019)

Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children’s Oncology Group (ANZCHOG) Study
por: Ryan, Anne L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dr973453ja5gnai5dhkiodesgu